← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
AXIS Capital grew revenue, net income fell, capital returns shifted toward buybacks, and insider activity was sales-only.
The read at a glance✓ Audited against SEC data
- Business mix — Specialty insurance and reinsuranceNote
- Revenue — Revenue rose 10.2%OK
- Profit — Net income fell 6.7%Watch
- Cash — Free cash flow unavailableNote
- Balance sheet — Equity rose 4.4%OK
- Insiders — 0 buys / 6 sellsWatch
- Accounting — Altman-Z, Beneish-M, and earnings-quality unavailableNote
Business
AXIS Capital is a specialty insurer and reinsurer with insurance and reinsurance lines exposed to catastrophe, liability, cyber, marine, aviation, accident and health, and other specialty risks.
Where the revenue comes from
Fiscal 2025, as AXIS CAPITAL HOLDINGS LTD reports it. History and quarterly detail are in the app.
- Insurance$4.3B
- Reinsurance$1.4B
Leadership changes
From AXIS CAPITAL HOLDINGS LTD's own filings, the day they're filed.
- Pradip Patiath · Directors · appointmenteff. 2026-06-15
- Matthew Kirk · Chief Financial Officer · appointmenteff. 2026-03-31
- A. Tom Bolovinos · Chief Accounting Officer · appointmenteff. 2025-12-02
Latest filings
- 10-Q · Quarterly report2026-07-28
- 8-K · Company announcement2026-07-28
- 8-K · Company announcement2026-06-15
- 8-K · Company announcement2026-05-18
- 8-K · Company announcement2026-04-29
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about AXIS CAPITAL HOLDINGS LTD, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.